

Clone #	Kd [nM]
16-B-03	0,67
16-B-05	1,07
16-B-07	0,99
23-B-04	0,58
42-B-02	0,50
42-B-04	0,48

Fig. 1




Fig. 2a




Fig. 2b




Fig. 3a




Fig. 3b




Fig. 4a




Fig. 4b




Fig. 5a




Fig. 5b




Fig. 6a




Fig. 6b




Fig. 7a




Fig. 7b




Fig. 8a




Fig. 8b




Fig. 9a




Fig. 9b




Fig. 10a




Fig. 10b




Fig. 11a




Fig. 11b




Fig. 12a




Fig. 12b




Fig. 13a




Fig. 13b




Fig. 14a




Fig. 14b




Fig. 15




Fig. 16a




Fig. 16b




Fig. 16b ctd'




Fig. 16b ctd'




Fig. 16b ctd'




Fig. 16b ctd'




Fig. 17a

1 => 30% loss of binding vs wild type	human IRhom2 with deletions/substitutions					
	humanised antibody clones					
	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04
2 => 60% loss of binding vs wild type						
3 => 95% loss of binding vs wild type						
Q502R	-	-	-	-	-	-
N503A	1	1	1	1	1	1
D504A	-	-	-	-	-	-
H505R	-	-	-	-	-	-
H505A	-	-	-	-	-	-
S506A	-	-	-	-	-	-
G507A	-	-	-	-	-	-
C508A	1	1	1	2	2	1
I509V	-	-	-	-	-	-
I509A	-	-	-	-	-	-
Q510A	-	-	-	-	-	-
T511A	-	-	-	-	-	-
Q512L	-	-	-	-	-	-
Q512S	-	-	-	-	-	-
Q512A	-	-	-	-	-	-
R513K	-	-	-	-	-	-
R513E	-	-	-	-	-	-
R513A	-	-	-	-	-	-
K514E	-	-	-	-	-	-
K514A	-	-	-	-	-	-
D515E	-	-	-	-	-	-
D515A	-	-	-	-	-	-
S517A	-	-	-	-	-	-
E518S	-	-	-	-	-	-
E518A	-	-	-	-	-	-
T519A	-	-	-	-	-	-

Fig. 17b

1 => 30% loss of binding vs wild type	human rRhom2 with deletions/substitutions						
2 => 60% loss of binding vs wild type	humanised antibody clones						
3 => 95% loss of binding vs wild type	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04	
L520A	-	-	-	-	-	-	-
A521S	-	-	-	-	-	-	-
T522V	-	-	-	-	-	-	-
T522A	-	-	-	-	-	-	-
F523W	-	-	-	-	-	-	-
V524A	-	-	-	-	-	-	-
K525A	-	-	-	-	-	-	-
W526A	1	1	1	1	1	1	1
Q527P	1	1	1	1	1	1	1
Q527A	-	-	-	-	-	-	-
D528N	-	-	-	-	-	-	-
D528I	-	-	-	1	-	-	1
D528A	-	-	-	1	-	-	1
D529H	-	-	-	1	1	1	1
D529A	-	-	1	-	-	-	1
T530P	1	1	1	1	1	1	1
T530A	-	-	-	1	-	-	1
G531S	1	1	1	1	1	1	1
G531A	-	1	1	-	-	-	-
P532A	1	1	1	2	1	1	1
P533-	3	3	3	3	3	3	3
P533A	-	1	1	1	1	1	1
M534S	-	1	-	1	1	1	1
M534-	3	3	3	3	3	3	3
M534A	-	1	1	1	1	1	1

Fig. 17b ctd'

1 => 30% loss of binding vs wild type	human iRhomb2 with deletions/substitutions					
	humanised antibody clones					
2 => 60% loss of binding vs wild type	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04
3 => 95% loss of binding vs wild type						
D535-	3	3	3	3	3	3
D535A	1	1	1	2	2	1
K536-	3	3	3	3	3	3
K536A	3	3	3	3	3	3
S537E	-	-	-	2	2	2
S537A	-	-	-	-	-	-
D538L	-	-	-	-	-	-
D538A	-	-	-	-	-	-
L539A	2	1	2	3	3	3
G540S	-	-	-	-	-	-
G540A	-	-	-	-	-	-
Q541H	-	-	-	-	-	-
Q541A	-	-	-	-	-	-
K542A	1	1	1	-	-	-
R543Q	1	1	1	2	2	2
R543A	1	1	1	3	2	2
T544P	1	1	1	1	1	1
T544Q	-	-	-	-	-	-
T544A	-	-	-	-	-	-
S545F	-	-	-	-	-	-
S545A	-	-	-	-	-	-
G546A	1	1	1	1	1	1
A547V	-	-	-	-	-	-
A547S	-	-	-	-	-	-
V548A	-	-	-	-	-	-
H550A	-	-	-	-	-	-

Fig. 17b ctd'

1 => 30% loss of binding vs wild type	human iRhomb2 with deletions/substitutions					
	humanised antibody clones					
2 => 60% loss of binding vs wild type	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04
3 => 95% loss of binding vs wild type	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04
Q551A	-	-	-	-	-	-
P553A	-	-	-	-	-	-
R554A	-	-	-	-	-	-
T555V	-	-	-	-	-	-
T555A	-	-	-	-	-	-
E557D	-	-	-	-	-	-
E557A	-	-	-	-	-	-
E558A	-	-	-	-	-	-
A560S	-	-	-	-	-	-
S561A	-	-	-	1	-	-
S562E	-	-	-	-	-	-
S562A	-	-	-	-	-	-
G563D	-	-	-	-	-	-
G563A	-	-	-	-	-	-
A564P	-	-	-	-	-	-
A564S	-	-	-	-	-	-
H565A	-	-	-	-	-	-
I566E	-	-	-	2	1	1
I566A	-	-	-	-	-	-
P568A	-	-	-	-	-	-
D569E	-	-	-	-	-	-
D569A	-	-	-	-	-	-
D570A	-	-	-	-	-	-
I571A	-	-	-	-	-	-
T572A	-	-	-	-	-	-
K573A	-	-	-	-	-	-

Fig. 17b ctd'

1 => 30% loss of binding vs wild type	human iRhomb2 with deletions/substitutions					
	humanised antibody clones					
2 => 60% loss of binding vs wild type	#16-B-03	#16-B-05	#16-B-07	#23-B-04	#42-B-02	#42-B-04
3 => 95% loss of binding vs wild type						
P575A	-	-	-	-	-	-
I576A	-	-	-	-	-	-
T578A	-	-	-	-	-	-
E579K	-	-	-	-	-	-
E579A	-	-	-	-	-	-
Q580N	-	-	-	-	-	-
Q580A	-	-	-	-	-	-
A581S	-	-	-	-	-	-
R582A	-	-	-	-	-	-
S583G	-	-	-	-	-	-
S583A	-	-	-	-	-	-
N584A	-	-	-	-	-	-
H585A	-	-	-	-	-	-
T586A	-	-	-	-	-	-
G587N	-	-	-	-	-	-
G587A	-	-	-	-	-	-
F588H	-	-	-	-	-	-
F588A	-	-	-	-	-	-
L589P	-	-	-	-	-	-
L589A	-	-	-	-	-	-
H590A	-	-	-	-	-	-
M591A	-	-	-	-	-	-
D592A	-	-	-	-	-	-
C593A	-	-	-	-	-	-
E594V	-	-	-	-	-	-

Fig. 17b ctd'




Fig. 18a




Fig. 18b




Fig. 19a




Fig. 19b




Fig. 20a




Fig. 20b




Fig. 21a




Fig. 21b